Transplantation of BDNF Gene Recombinant Mesenchymal Stem Cel ls and Adhesive Peptide-modified Hydrogel Scaffold for Spinal Cord Repa ir

Li, Liming; Huang, Lingling; Jiang, Xinyi; Chen, Jia-Chen; Ouyang, Hongwei; J, Gao

doi:10.2174/1566523218666180413150023

Cited by 39 publications

(15 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Encapsulated BDNF-producing fibroblasts in alginate-poly- L -ornithine survived for at least one month after being transplanted into the site of cervical spinal cord injury in rats without immunosuppression [ 363 ]. Transfection of BDNF gene recombinant MSCs via the adhesive peptide PPFLMLLKGSTR-modified scaffold improved cell survival and BDNF expression [ 368 ]. Alginate-based compositions have also been used to transport NSCs-BDNF and BMSCs-BDNF, maintaining long-term survival and proliferation of cells, as well as controlled release of BDNF [ 362 ].…”

Section: Bdnf-targeting Strategies For Ad Modificationmentioning

confidence: 99%

Brain-derived neurotrophic factor in Alzheimer’s disease and its pharmaceutical potential

Gao

Zhang

Sterling

et al. 2022

Transl Neurodegener

236

View full text Add to dashboard Cite

Synaptic abnormalities are a cardinal feature of Alzheimer’s disease (AD) that are known to arise as the disease progresses. A growing body of evidence suggests that pathological alterations to neuronal circuits and synapses may provide a mechanistic link between amyloid β (Aβ) and tau pathology and thus may serve as an obligatory relay of the cognitive impairment in AD. Brain-derived neurotrophic factors (BDNFs) play an important role in maintaining synaptic plasticity in learning and memory. Considering AD as a synaptic disorder, BDNF has attracted increasing attention as a potential diagnostic biomarker and a therapeutical molecule for AD. Although depletion of BDNF has been linked with Aβ accumulation, tau phosphorylation, neuroinflammation and neuronal apoptosis, the exact mechanisms underlying the effect of impaired BDNF signaling on AD are still unknown. Here, we present an overview of how BDNF genomic structure is connected to factors that regulate BDNF signaling. We then discuss the role of BDNF in AD and the potential of BDNF-targeting therapeutics for AD.

show abstract

Section: Bdnf-targeting Strategies For Ad Modificationmentioning

confidence: 99%

Brain-derived neurotrophic factor in Alzheimer’s disease and its pharmaceutical potential

Gao

Zhang

Sterling

et al. 2022

Transl Neurodegener

236

View full text Add to dashboard Cite

show abstract

“… Li et al (2018a) reported that the use of an HA scaffold modified with adhesive peptides for the treatment of SCI. MSCs with recombinant brain-derived neurotrophic factor exhibited improved cell survival and sustained gene expression in vitro .…”

Section: Stem Cells (Scs)mentioning

confidence: 99%

Technological Advances of 3D Scaffold-Based Stem Cell/Exosome Therapy in Tissues and Organs

Feng

Waqas

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

“…In a recent study, Li-Ming Li and colleagues applied a three-dimensional gene transfection technology by transfecting MSCs with brain derived neurotrophic factor (BDNF) gene using the liposomal gene carrier, ScreenFect ® A [129]. To improve gene expression as well as cellular survival after in vivo implantation of MSCs, an adhesive peptide (PPFLMLLKGSTR)-modified hydrogel scaffold was constructed using hyaluronic acid.…”

Section: Scaffoldsmentioning

confidence: 99%

Mesenchymal Stem Cells as a Gene Delivery Tool: Promise, Problems, and Prospects

et al. 2021

View full text Add to dashboard Cite

The cell-based approach in gene therapy arises as a promising strategy to provide safe, targeted, and efficient gene delivery. Owing to their unique features, as homing and tumor-tropism, mesenchymal stem cells (MSCs) have recently been introduced as an encouraging vehicle in gene therapy. Nevertheless, non-viral transfer of nucleic acids into MSCs remains limited due to various factors related to the main stakeholders of the process (e.g., nucleic acids, carriers, or cells). In this review, we have summarized the main types of nucleic acids used to transfect MSCs, the pros and cons, and applications of each. Then, we have emphasized on the most efficient lipid-based carriers for nucleic acids to MSCs, their main features, and some of their applications. While a myriad of studies have demonstrated the therapeutic potential for engineered MSCs therapy in various illnesses, optimization for clinical use is an ongoing challenge. On the way of improvement, genetically modified MSCs have been combined with various novel techniques and tools (e.g., exosomes, spheroids, 3D-Bioprinting, etc.,) aiming for more efficient and safe applications in biomedicine.

show abstract

Transplantation of BDNF Gene Recombinant Mesenchymal Stem Cel ls and Adhesive Peptide-modified Hydrogel Scaffold for Spinal Cord Repa ir

Abstract: The study developed a promising implantation system for therapy of severe spinal cord injury and provided the first understanding of Screenfect® A about its functions on stem cell therapy for nerve tissue repair as well as three-dimentional gene expression.

Cited by 39 publications

References 0 publications

Brain-derived neurotrophic factor in Alzheimer’s disease and its pharmaceutical potential

Brain-derived neurotrophic factor in Alzheimer’s disease and its pharmaceutical potential

Technological Advances of 3D Scaffold-Based Stem Cell/Exosome Therapy in Tissues and Organs

Mesenchymal Stem Cells as a Gene Delivery Tool: Promise, Problems, and Prospects

Contact Info

Product

Resources

About